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Abstract
Aortic valve disease (AVD) is a common condition with a progressive natural
history, and presently, there are no pharmacologic treatment strategies. Elastic
fiber fragmentation (EFF) is a hallmark of AVD, and increasing evidence
implicates developmental elastic fiber assembly defects. Emilin1 is a glycopro-
tein necessary for elastic fiber assembly that is present in both developing and
mature human and mouse aortic valves. The Emilin1-deficient mouse (Emil-
in1/) is a model of latent AVD, characterized by activated TGFb/MEK/p-
Erk signaling and upregulated elastase activity. Emilin1/ aortic valves
demonstrate early EFF and aberrant angiogenesis followed by late neovascular-
ization and fibrosis. The objective of this study was to test the effectiveness of
three different targeted therapies. Aged (12–14 months) Emilin1/ mice were
treated with refametinib (RDEA-119, MEK1/2 inhibitor), doxycycline (elastase
inhibitor), or G6-31 (anti-VEGF-A mouse antibody) for 4 weeks. Refame-
tinib- and doxycycline-treated Emilin1/ mice markedly reduced MEK/p-Erk
activation in valve tissue. Furthermore, both refametinib and doxycycline
attenuated elastolytic cathepsin K, L, MMP-2, and MMP-9 activation, and
abrogated macrophage and neutrophil infiltration in Emilin1/ aortic valves.
RNAseq analysis was performed in aortic valve tissue from adult (4 months)
and aged (14 months) Emilin1/ and age-matched wild-type control mice,
and demonstrated upregulation of genes associated with MAPK/MEK/p-Erk
signaling and elastases at the adult stage and inflammatory pathways at the
aged stage controlling for age. These results suggest that Erk1/2 signaling is an
important modulator of early elastase activation, and pharmacological inhibi-
tion using refametinib may be a promising treatment to halt AVD progression
Introduction
Aortic valve disease (AVD) is a common cause of cardio-
vascular morbidity and mortality (Mozaffarian et al. 2015).
Presently, there are no pharmacologic treatment options
available for preventing, reversing, or halting the progres-
sion of AVD (Rajamannan et al. 2011). Therefore, surgery
remains the primary treatment approach and this is
restricted to severe “end stage” disease (Nishimura et al.
2014). Valve replacement procedures are associated with
significant complications, and the need for reintervention
is common (Gallegos 2006; Keane et al. 1993). Accordingly,
there is a crucial need for new pharmacologic treatment
options that stop AVD progression, precluding the need for
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surgical intervention. The National Heart, Lung, and Blood
Institute has identified the need for new medical strategies
applicable to early AVD (Rajamannan et al. 2011). Animal
models that recapitulate the natural history of human AVD
are required to optimally execute preclinical studies that
test new therapeutic targets.
The Emilin1/ mouse is a model of latent fibrotic
AVD (Munjal et al. 2014). Emilin1 is an elastogenic
glycoprotein that inhibits TGFb-mediated MEK/Erk1/2
signaling, and Emilin1 deficiency results in increased
p-Erk1/2 expression, elastase activation, and Vegf-
mediated aberrant angiogenesis in aortic valve tissue
(Munjal et al. 2014). Interestingly, constitutively hyperac-
tive Erk1/2 signaling results in valve maturation defects
(Krenz et al. 2008). Importantly, the MAPK/p-Erk1/2
pathway regulates the maladaptive response of valve inter-
stitial cells (VICs), and inhibition of p-Erk1/2 reduced
this response in vitro (Gu and Masters 2009). Previous
reports have shown a role for selective MEK1/2 inhibition
in a mouse model of Marfan syndrome to treat thoracic
aortic aneurysm (Holm et al. 2011), and MEK1/2 inhibi-
tors mitigate pathological remodeling in mouse models of
pulmonary fibrosis (Mercer and D’Armiento 2006). Sev-
eral MEK1/2 inhibitors have successfully completed phase
II clinical trial testing for various solid tumors (Schmieder
et al. 2013). However, the potential in vivo therapeutic
role of p-Erk1/2 inhibition for AVD has not been tested.
Elastases are proteolytic enzymes that have the ability
to cleave the elastic fibers resulting in elastic fiber frag-
mentation (EFF), a hallmark of AVD (Aikawa et al. 2009;
Basalyga et al. 2004; Fondard et al. 2005; Schoen 1997;
Vesely 1998). EFF, or elastase-mediated elastic fiber
assembly abnormalities, may contribute to AVD initiation
and progression (Fondard et al. 2005; Hinton et al. 2006;
Perrotta et al. 2011). Elastase inhibitors have been found
to be successful in halting the progression of aortopathy
and preventing aortic dissection (Xiong et al. 2012).
Doxycycline, a nonspecific elastase inhibitor, is an FDA
approved drug for elastolytic matrix metalloproteinase
(MMP) inhibition in patients with periodontal disease
(Gapski et al. 2009). Interestingly, one randomized clini-
cal trial demonstrated that doxycycline had a pronounced
effect mitigating inflammation in patients with aortopathy
(Lindeman et al. 2009). Previous studies have suggested
p-Erk1/2 may be an important upstream regulator of elas-
tase activation in aortic pathophysiology (Ghosh et al.
2012). However, the role of Erk1/2 signaling during AVD
progression has not been demonstrated.
The goal of this study was to test three new pharmaco-
logic treatment strategies for AVD in the Emilin1-defi-
cient mouse model, namely p-Erk1/2 inhibition, elastase
inhibition, and Vegf inhibition. We demonstrated the
effectiveness of MEK/p-Erk inhibition using refametinib,
and to a lesser extent elastase inhibition using doxycy-
cline. These findings have important clinical implications
because understanding early disease mechanisms promises
to identify new medical therapies. Refametinib with or
without adjunct doxycycline warrants further investiga-
tion as a potential new medical therapy for AVD.
Methods
Study design
Emilin1/ and Emilin1+/+ littermate mice were studied
at 12 months of age. Mice were maintained on a C57Bl6
genetic background, and genotyping was performed as
described previously (Munjal et al. 2014). Animals were
divided into five groups: (1) vehicle-treated Emilin1+/+
mice (negative control); (2) vehicle-treated Emilin1/
mice (positive control); (3) Emilin1/ mice treated with
refametinib (RDEA-119), a selective MEK1/2 inhibitor
(p-Erk1/2 inhibition); (4) Emilin1/ mice treated with
doxycycline (nonspecific elastase inhibition); and (5)
Emilin1/ mice treated with G6-31 (Vegf-A inhibition)
(Fig. 1). All mice were treated for 4 weeks, including the
vehicle control group. The Cincinnati Children’s Research
Foundation Institutional Animal Care and Use Commit-
tee approved all protocols.
Refametinib (RDEA-119, BAY 869766), a MEK1/2 specific
allosteric inhibitor (Chemical Genomics Center, NHGRI,
National Institutes of Health), was administered twice daily
using oral gavage at 25 mg/kg body weight per dose. RDEA-
119 was dissolved in DMSO at 10 mmol/L (Holm et al.
2011; Iverson et al. 2009; Wylie-Sears et al. 2014) and
reconstituted in 10% 2-hydroxypropyl-beta-cyclodextrin
(Sigma-Aldrich, St. Louis). Doxycycline (0.5 g/L; Sigma)
was delivered in drinking water based on established proto-
cols (Chung et al. 2008; Xiong et al. 2008). Because doxycy-
cline is light sensitive, water was shielded from all light and
changed periodically every 2 days. G6-31, an IgG1 mono-
clonal antibody that inhibits angiogenesis by neutralizing
Vegf-A (generously provided by Genentech Inc., San Fran-
cisco, CA), was given twice weekly for 4 weeks at a dose of
0.5 mg/kg by intraperitoneal injection. The concentrated
drug was dissolved in 0.9% normal saline (Liang et al.
2006). The drug-vehicle control group received 10%
2-hydroxypropyl-beta-cyclodextrin, oral gavage, 0.9% nor-
mal saline, via an intraperitoneal route.
Histology and immunohistochemistry
Mouse hearts were processed as previously described
(Hinton et al. 2006; Munjal et al. 2014). Harts and
Masson trichrome stains were used. Immunohistochem-
istry was performed to assess markers of p-Erk1/2
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signaling, elastase activation, angiogenesis, macrophage
infiltration, and proliferation (Table S3). All antibody
protocols used streptavidin/biotin colorimetry and
diaminobenzidine detection. The slides were examined
using Nikon NIS elements software. Immunostaining for
Mmps and cathepsins were quantified using the
National Institutes of Health (NIH) Image J software
(http://rsb.info.nih.gov/ij/), as previously described (Jen-
sen 2013).
Western blotting
Analyses were performed on aortic valves (5 valves/experi-
ment), as described previously (Munjal et al. 2014). A
bicinchoninic acid protein assay kit (Pierce) was used to
estimate total protein, and 30 lg of protein lysate was
loaded onto 8–12% SDS–PAGE gels and then transferred
onto nitrocellulose membranes. The membranes were
blocked with 3% non-fat dry milk in TBS-T and incu-
bated with primary for MMP-2 and p-Erk1/2 antibodies
overnight at 4°C. Immunoblots were probed with HRP-
conjugated secondary antibodies for 1 h at room tempera-
ture and developed using chemiluminiscence (Amersham
Biosciences). After stripping using the stripping buffer
(Thermo Fischer), the blots were reprobed with Gapdh
(Abcam) or t-Erk1/2 antibody (Cell signaling). Signal
intensity was quantified using the NIH Image J software.
The arbitrary pixel densities of each protein were normal-
ized to GAPDH or t-Erk1/2. Band intensities on the west-
ern blots were quantified using Image Studio Lite software
(Li-COR).
RNA-Seq analysis
Aortic valves were dissected according to a protocol
developed in the laboratory (Hinton et al. 2010; Munjal
et al. 2014), pooled in RNALater (n = 10 mice/
experiment) and stored according to manufacturer’s rec-
ommendations. Total RNA was extracted using the micro
RNEasy Kit (Qiagen, Valencia, CA), and RNA quality
was assessed using the Agilent Bioanalyzer 2100. RNA
was then prepared for sequencing using the Illumina
mRNA-seq Sample Prep Kit. The generated RNA-seq
libraries were subjected to high-throughput 50 bp single-
end RNA-sequencing at a read depth of >50 million
reads utilizing the Illumina Hi-Seq 2500 machine. All
sequenced reads were aligned to the mus musculus (mm9
sequence database) subset of RefSeq using TopHat, and
then processed with Cufflink to generate the transcrip-
tome (Brunskill et al. 2014a,b; Potter and Brunskill
2014).
RNA-Seq BAM files were imported into AvadisNGS
software for further analysis. The RNA-Seq data were
then filtered for misaligned and/or duplicate reads. The
filtered data was normalized using RPKM (reads per kilo-
base per million) and filtered again at a threshold of 10
RPKM. Differential expression analysis was performed on
the filtered data set (>10 RPKM) to identify genes with a
>2-fold change.
In order to monitor the natural history of disease pro-
gression, the differentially expressed gene due to Emilin1
deficiency was monitored at early (4 month) and late
(12–14 month) stages, corresponding with time points
before and after disease onset, using enrichment analysis
and compared with wild-type control mice. Genes corre-
sponding to differentially expressed transcript clusters
were selected for display in hierarchical clustering, with a
threshold P-value cutoff of 0.05 using an one-way
ANOVA. Differentially expressed genes were clustered
using Topp Cluster web server application for compre-
hensive analysis of multiple genes list or biological path-
ways in early and the late stage. The log2-transformed
data were preprocessed by median centering, and then
hierarchically clustering method (https://toppcluster.cc
Figure 1. Preclinical study treatment strategy in Emilin1-deficient mouse model of AVD. Emilin1 deficiency results in early p-Erk1/2, elastase
and Vegf activation at 4 month followed by the manifestation of AVD, characterized by fibrosis, neovascularization, and inflammation, at
12 months of age and premature death at 15–18 months of age. Treatment was initiated at 12 month age (arrow) and all five treatment
groups were treated for 1 month period using drugs as mentioned.
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hmc.org/). Subsequently, enrichment maps and Venn dia-
grams were generated using cytoscape software (Barnette
et al. 2014; Brunskill et al. 2014a,b; Potter and Brunskill
2014).
Quantitative RT-PCR
RNA from aortic valves (4 valves/experiment) was iso-
lated from vehicle- and drug-treated mice using Trizol.
As previously reported, cDNA was generated using
~500 ng isolated RNA and amplified by PCR using gene-
specific primers (Table S4)(Hinton et al. 2010; Munjal
et al. 2014). Ct values were obtained using Bio-Rad
software. The DDCt method was used to represent
mRNA fold change. The experiments were performed in
triplicate.
Human valve tissue
Aortic valve specimens were obtained from nonsyndromic
patients with isolated AVD and undergoing aortic valve
replacement (affected), and from age-matched individuals
who died of noncardiac causes at the time of autopsy
(control). AVD patients were stratified by age into early-
onset (0–40 years) and late-onset (41–85 years) groups.
Patients with a history of rheumatic heart disease or
infective endocarditis were excluded. Control aortic valves
from patients of similar ages were obtained at autopsy
from individuals who died of noncardiac causes with a
maximum ischemic time of 24 h. Aortic valve tissues
were fixed in 10% formalin, dehydrated through a graded
ethanol series, washed in xylenes, and embedded in paraf-
fin wax and sectioned. Tissue slides were subsequently
processed and stained as described previously (Wirrig
et al. 2011). These studies were approved by the Institu-
tional Review Boards at Cincinnati Children’s Hospital
Medical Center and Good Samaritan Hospital (Cincin-
nati, Ohio).
Quantitative analysis of desmosine in
human aortic valve tissue
Desmosine is an amino acid that resides within the
crosslinking network of the mature elastic fiber. Des-
mosine quantitative assay is a marker for elastic fiber
fragmentation that also reflects elastin content (Brown-
Augsburger et al. 1996). Frozen human aortic valve tissue
isolated from patients undergoing valve replacement sur-
gery was hydrolyzed in 6 N HCl at 100°C for 24 h, evap-
orated to dryness, and redissolved in water. The
hydrolysates were evaporated to dryness, redissolved in
water, and desmosine content was then measured as
described previously (Starcher and Conrad 1995).
Results
Refametinib normalizes p-Erk1/2 expression
and attenuates EFF in Emilin1/ aortic valve
tissue
In aged Emilin1/ mice with AVD characterized by EFF
(Munjal et al. 2014), both refametinib and doxycycline, but
not G6-31, restored normal elastic fiber morphology
(Fig. 2A–E). Refametinib demonstrated significant suppres-
sion of p-Erk1/2 activation as evidenced by western blot and
immunohistochemistry. Interestingly, doxycycline showed
similar results. G6-31 resulted in a mild reduction in p-Erk1/
2 expression that was not statistically significant (Fig. 2F–K).
However, no change in neovessel formation or collagen depo-
sition was seen in any treatment groups (data not shown).
Densitometry evaluation further substantiated the findings
showing significant reduction of p-Erk1/2 to t-Erk1/2 fold
change in Emilin1/ aortic valves when treated with refame-
tinib or doxycycline (Fig. 2L). Taken together, these findings
demonstrate that refametinib effectively suppresses p-Erk1/2
in diseased tissue and restores elastic fiber morphology.
Refametinib inhibits elastolytic enzymes in
aortic valve tissue
Emilin1/ aortic valves showed increased expression and
activities of the elastolytic enzymes Mmp-2 and Mmp-9,
indicative of pathological matrix remodeling due to Emilin1
deficiency. Interestingly, Mmp-9 expression was suppressed
with refametinib or doxycycline treatments (Fig. 3C, E). G6-
31 treatment, on the other hand, had no effect on Mmp-2 or
Mmp-9 expression. We also examined cathepsins K, S and L
in the extracellular matrix (ECM) remodeling established
since studies have reported a role in for these enzymes in aor-
tic valve disease (Helske et al. 2007). Emilin1/ aortic valves
demonstrate a robust increase in the expression of cathepsins
L, K, and S in aged aortic valve tissue (Fig. 3L,Q,V). Doxycy-
cline or refametinib treatment inhibits cathepsins K and L
(Fig. 3M,R,O,T), consistent with previous studies showing
either elastase or MEK1/2 inhibition reduces cathepsin K
expression (Franco et al. 2011; Ihn et al. 2015). On the con-
trary, doxycycline or refametinib treatment did not effect
cathepsin S expression. Overall, this suggests that p-Erk1/2
inhibition using refametinib inhibits elastase activation and
pathological matrix remodeling in Emilin1/ aortic valves.
Refametinib treatment resulted in a
reduced inflammatory response but did not
change aberrant angiogenesis
Aged Emilin1/ aortic valves manifest fibrosis, neovascu-
larization, and inflammation (Munjal et al. 2014). To
2017 | Vol. 5 | Iss. 5 | e13152
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examine inflammation, IHC was performed using the
macrophage marker Mac-3, which identifies differentiated
macrophages. Emilin1/ valves showed significantly
increased Mac-3 when compared with control valves, and
refametinib or doxycycline treatment, but not G6-31
treatment, results in a dramatic reduction in Mac-3
(Fig. 4). Mmp-12 and neutrophil elastase (N-elastase),
nonspecific markers associated with inflammation, were
both dramatically increased in Emilin1/ valves, but
Mmp-12 and N-elastase were reduced only slightly in all
treatment groups. G6-31-treated Emilin1/ valves
showed reduction in Vegf-A expression, however, refame-
tinib- and doxycycline-treated valves showed no change
in Vegf-A expression (data not shown). Emilin1/ aortic
valves are characterized by a progressive increase in the
proliferative index and increased myofibroblast like phe-
notype in VIC’s (Munjal et al. 2014), but neither the
proliferation index nor the degree of myofibroblast inter-
stitial cell activation was different with any treatment, as
evidenced by p-HisH3 and SM-22 staining, respectively
(data not shown). These findings suggest that refametinib
abrogated macrophage and neutrophil infiltration in
Emilin1/ aortic valves, but did not halt the pathologic
myoproliferative VIC response.
RNAseq analysis demonstrated discrete
early and late disease processes in Emilin1
deficient aortic valve tissue
In order to identify molecular signatures involved in
AVD progression in Emilin1/ mice, transcriptome anal-
ysis was performed at adult (4-month-old) and aged (14–
18-month-old) stages in Emilin1+/+ and Emilin1/ aortic
valves. RNAseq analyses revealed a total of 470 and 456
A B C D E
F
K
L
G H I J
Figure 2. Refametinib, doxycycline, and G6-31 treatment effects in Emilin1-deficient mice. Harts micrograph showed elastic fiber assembly
defects and EFF in Emilin1-/- aortic valves (arrowheads, B), and intact cusp layers, namely the fibrosa (F), spongiosa (S), and ventricularis (V) in
Emilin1+/+ valve (A), and reduction in EFF with refametinib (arrows, C) or doxycycline (arrows, E) treatment in aortic valve tissue. IHC shows
p-Erk1/2 activation in Emilin1-/- aortic valves (G) and dramatic reduction in p-Erk1/2 expression in response to refametinib (H) or doxycycline
treatment (J), and unaltered with G6-31 (I) treatment. Western blot analysis (K) and corresponding densitometry analysis (L) show significant
reduction in p-Erk1/2 activation when treated with refametinib or doxycycline (n = 7–8/group, P < 0.0001; * different from Emilin1+/+;
# different from vehicle-treated Emilin1/). EFF, Elastic fiber fragmentation.
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genes that were differentially expressed (twofold,
P < 0.05) at adult and aged stages, respectively (Fig. S2).
We studied whether the differentially expressed genes
were enriched for specific signaling pathways. Genes
involved in biological functions such as extracellular
matrix disassembly, cartilage development, angiogenesis,
and mechanical stimuli response elements were signifi-
cantly enriched in Emilin1/ adult aortic valves
(Fig. S2). In addition, significant enrichment was found
in genes involving TGFb signaling in Emilin1/ adults
when compared with age-matched controls. Aged Emil-
in1/ aortic valves demonstrated significant enrichment
Mmp-9
F G
BA
Mmp-2
Cath K
Cath L
Cath S
K L
P Q
U V
EC D
H I
M N
R S
W X
J
O
T
Y
f
s
v
Emilin1–/–
vehicle
Emilin1+/+ Emilin1–/–
refametinib
Emilin1–/–
 G6-31
Emilin1–/–
 doxycycline
Figure 3. Refametinib and doxycycline mitigates pathological remodeling in Emilin1/ aortic valve tissue. IHC showing Mmp-9 (A–E), Mmp-2
(F–J), cathepsin L (K–O), cathepsin K (P–T), and cathepsin S (U–Y) content and location. Mmp-9 expression was increased in vehicle-treated
Emilin1/ valves and was abrogated with doxycycline (D) or refametinib (E) treatment. Mmp-2, which is expressed in Emilin1/ aortic valves;
on the other hand, it was unchanged with any treatment (H–J). Figure shows increased expression of cathepsin L (arrows, L) localized to the
interstitial cells and cathepsin K (arrows, Q) localized to endothelial as well as interstitial cells in Emilin1/ aortic valves, and this expression was
dramatically reduced when treated with doxycycline (N, S) or refametinib (O,T). Cathepsin S expression was also increased in the interstitial cells
of Emilin1/ valves (V) but unchanged with any treatment.
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in genes associated with inflammation. At least 17 genes
were differentially expressed in both adult and aged Emil-
in1/ mice, 4 are shown in the enrichment map (ma-
roon nodes), suggesting different signaling pathways are
involved in early and late disease processes (Fig. S2).
Interestingly, control wild-type valves also demonstrate
281 differentially expressed genes due to aging. To vali-
date the targets of altered differential gene expression in
Emilin1 deficiency, additional IHC or QRT-PCR was per-
formed for selected genes (Fig. S3). IHC revealed
increased expression of the profibrotic gene Periostin, a
marker for osteogenic procalcific activity gene Spp-1 (os-
teopontin) and the proinflammation gene Ptx-3 (Pentax-
trin) in Emilin1-/- aortic valves. Our RNAseq findings
demonstrated elevated Ptx-3 expression at both adult and
aged stages in Emilin1-deficient valves. Findings were cor-
roborated using QRT-PCR (Fig. S3). Furthermore, QRT-
PCR showed that Mmp-2 expression was progressively
increased in aged null valves when compared to wild-type
controls (Fig. S3). In addition, Emilin1-/- vascular smooth
muscle cells (VSMCs) isolated from aortic root demon-
strated a robust increase in p-Erk1/2 expression when
stimulated with the osteogenic media (OM). Neither
aorta nor aortic valve demonstrated spontaneous gross
calcification at any age in the Emilin1/ mice (Fig. S4).
VSMC’s were isolated and cultured from the aortic root
of Emilin1+/+ Emilin1/ mice. Emilin1/ VSMCs calcify
as seen by alizarin red staining when compared with
Emilin1+/+ cells. Osteocalcin and Runx-2 (ossification
markers) were upregulated in VSMC’s cultured in OM
(Fig. S4). Osteogenic media induces p-Erk1/2 activation
and downregulation of VEGF-A, suggesting VSMC calcifi-
cation is mediated by p-Erk1/2 activation. Taken together,
this suggests AVD pathogenesis in Emilin1/ valves is
dynamic, characterized by early perturbation in TGFb sig-
naling and ECM, followed by late inflammation and the
manifestation of overt disease.
Human AVD shows progressive p-ERK1/2
and elastase activation
To extend these observations to human tissue and deter-
mine the timing of potential p-ERK1/2 activation in the
context of human AVD, p-ERK1/2 was examined using
IHC. All human valves were processed within 6 h if not
immediately. These studies demonstrated increased p-
A B C D E
F G H I J
K L M N O
Figure 4. Refametinib and doxycycline abrogates macrophage infiltration in Emilin1/ aortic valves. IHC shows Mac-3 staining in Emilin1/
aortic valve tissue that was completely obliterated with refametinib (C) or doxycycline (E), but not altered with G6-31 treatment (D). Mmp-12
was increased in hinge region of Emilin1/ aortic valves (arrows, G) and was slightly decreased with doxycycline (J), but unaltered with
refametinib (H) or G6-31 (I) treatment. Neutrophil elastase was increased in aortic valve intestinal cells of Emilin1/ mice (arrows, L), and this
increase was dramatically decreased with refametinib (M) or doxycycline (O) but unchanged with G6-31 (N).
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ERK1/2 expression in early-onset AVD in the absence of
inflammation when compared with healthy control aortic
valves, and p-ERK1/2 expression was increased further in
the presence of inflammation in late-onset AVD
(Fig. 5A–D). Cathepsin K was expressed ubiquitously in
early-onset AVD and age-matched control aortic valve tis-
sue, but continued to be expressed diffusely in late-onset
AVD while expression was restricted to the ventricularis
layer in age-matched controls (Fig. 5E–H). Cathepsin S is
increased modestly in early-onset AVD and increased dra-
matically in late-onset AVD specimens when compared to
age-matched controls, which show no expression
(Fig. 5M–P). Similarly, MMP-12, a macrophage-derived
elastase, was increased slightly in early-onset AVD but
increased significantly in late-onset AVD, including
around neovessels (Fig. 5I–J). These histological images
were quantified using Image J software, and comparisons
across groups were performed as shown in Table S2.
Taken together, these findings suggest that p-ERK1/2 and
elastolytic enzymes are misexpressed in early-onset AVD,
suggesting these early disease processes precede late
inflammation in human AVD.
To evaluate EFF in early and late-onset AVD, histologic
staining was performed, demonstrating marked elastic
fiber defects in early-onset AVD. In late-onset AVD, there
were similar elastic fiber abnormalities, including disper-
sion of fragments away from the ventricularis layer. Des-
mosine, a breakdown product of elastin as well as an
index of elastic fiber turnover, was quantified in healthy
and AVD specimens and showed significant reduction in
AVD when compared to control valves (Fig. 6).
Discussion
AVD is a burgeoning issue that effects more than 2% of
the general population, causing more than 25,000 deaths
annually in USA (Bonow et al. 2008; Nkomo et al. 2006).
Clinical trials examining statins (HMG coenzyme reduc-
tase inhibitors) have shown that these drugs neither
reverse AVD processes nor halt disease progression, e.g.,
the need for surgery and the timing of surgery is
unchanged (Mohler et al. 2007). This is due in part to
the relatively late initiation of therapy when tissue disease
is advanced and inflammation and extensive calcification
is already present, underscoring the importance of our
need to understand early pathogenesis and develop strate-
gies to begin therapy before these end stage milestones
are realized. A NIH Working Group examining the state
of research for AVD identified defining early intervention
strategies as a priority and consequently the need for ani-
mal models that recapitulate the natural history of human
AVD as well as molecular examination of the mechanisms
involved in disease initiation and early progression. In the
current study, we have evaluated the effectiveness of
Erk1/2 inhibition, elastase inhibition and Vegf inhibition
in reversing early disease processes in the Emilin1-defi-
cient mouse model of latent AVD (Munjal et al. 2014).
Our results suggest Erk1/2 inhibition using refametinib
and to a lesser extent elastase inhibition using doxycycline
are new potential therapeutic targets.
The results of the current study demonstrate that
increased noncanonical TGFb signaling in Emilin1/
aortic valves induces increased expression of both
p-Erk1/2 and elastases that eventually results in EFF and
inflammation. Refametinib or doxycycline treatment,
inhibits p-Erk1/2 or elastase expression; however, the fact
that neither drug returns p-Erk1/2 expression to its wild-
type levels suggests that p-Erk1/2 and elastase expression
potentiate reciprocally (Fig. 7). In this model, it is unclear
whether TGFb activation is canonical or noncanonical.
TGFb signaling results in Erk1/2 activation and this in
turn stimulates elastase expression ultimately leading to
the downstream effects including ECM abnormalities and
inflammation. However, we show that doxycycline not
only blocks downstream targets but also Erk1/2 phospho-
rylation (Fig. 2K and L), suggesting reversible elastases
and Erk1/2. Therefore, complex interactions between
TGFb targets are present in aortic valve tissue in the
Emilin1/ mouse model of latent AVD.
Previous studies have established aging as the major
risk factor for developing aortic valve disease (Rossebo
and Pedersen 2004). Our transcriptome analysis indicated
altered genes associated with ECM turnover and organiza-
tion at the adult stage and activation of genes involved in
inflammation at the aged stage in Emilin1-deficient aortic
valves. At least 17 genes were differentially expressed in
both adult and aged Emilin1/ mice (Fig. S2), 4 are
shown in the enrichment map (maroon nodes), suggest-
ing different signaling pathways are involved in early and
late disease processes (Fig. S1).
Interestingly, control wild-type valve tissue also
depicted altered gene expression related to inflammation,
albeit only a lesser degree, due to aging, suggesting the
mutant mouse may show advanced aging, consistent with
clinical studies identifying age-related inflammation as an
independent risk factor for AVD. The Emilin1-mutant
valve does not only grossly calcify at any age, including
24 months (unpublished), but also there are multiple
pieces of data that suggest elevated osteopontin is present
in Emilin1/ valve tissue. Moreover, recent studies sug-
gest that osteopontin has a role as an angiogenic factor,
in addition to its role as a marker for osteogenic procalci-
fic activity, and also our previous studies have shown ele-
vated level of proangiogenic factors in Emilin1/ valves
(Poggio et al. 2014). In addition, our studies have shown
vascular smooth muscle cells isolated from aortic root of
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Emilin1/ spontaneously calcify when stimulated with
osteogenic media. Also, osteopontin expression was
increased in both cell types in the presence of osteogenic
media. Taken together, aging may exacerbate AVD pro-
gression in genotype-predisposed (Emilin1/) valve tis-
sue, recapitulating human AVD pathogenesis that initiates
with perturbations in ECM remodeling and progresses to
advanced disease with inflammation.
The findings of the current study are relevant to
human disease. Human AVD is characterized by a vast
array of pathologic findings, and discerning primary and
secondary findings is critical to understanding natural his-
tory and identifying new therapeutic targets. In the cur-
rent study, our human data suggest that P-ERK1/2 was
localized more in the nuclei in the early-onset disease
valves in contrast with late-onset disease that showed
more pronounced expression in the matrix. We do not
have any evidence that these treatments rescued valve
fibrosis. Grossly, pentachrome staining did not demon-
strate a difference in collagen content with treatment and
quantitatively, QRT-PCR did not normalize fibrillar colla-
gens. The expression of proteolytic enzymes declined in
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Figure 5. Human AVD tissue demonstrates similar findings as mouse model. Progressive p-Erk1/2 activation in early (B) and late (D) onset AVD
when compared to age-matched WT controls. Cathepsin K was ubiquitously expressed in early controls (arrows, E, G) and early-onset AVD
(arrows, F, H). MMP-12 and cathepsin S were increased in early-onset AVD (arrows, J, N) compared to age-matched controls, and further
increased in late-onset AVD (arrows, L, P) compared to early-onset AVD.
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Emilin1-deficient valves when treated with refametinib,
suggesting a therapeutic role of MEK inhibition in miti-
gating pathological ECM remodeling and this might be
extrapolated to suggest that the progressive nature of
fibrosis would discontinue but the existing fibrosis would
be unchanged. We also showed a marked increase in
Cathepsin S expression in late-onset human AVD, that is
AVD associated with inflammation. Combined with
observations in the Emilin1/ mouse valves that showed
increased expression of elastolytic enzymes (Mmp-2,9,
and cathepsins K, L, and S), this suggests that early elas-
tase activation may be related to elastic fiber abnormali-
ties while late elastase activation may be secondary to
inflammatory processes and these patterns may be
distinct. Importantly, refametinib or doxycycline treat-
ment significantly decreased the expression of proteolytic
enzymes Mmp-9, and cathepsin K and L. Elastic fiber
degradation products have shown promise as biomarkers
of emerging disease states (Marshall et al. 2013). Previous
studies have shown that inhibition of MEK/2 is a poten-
tial therapeutic option for valve disease patients (Sauls
et al. 2015). Taken together, this suggests elastases may be
potential markers for early AVD pathogenesis, consistent
with our hypothesis that elastic fiber abnormalities play a
fundamental role in AVD initiation and progression prior
to inflammation.
This study has significant limitations. One limitation is
the lack of data examining the effects of combined therapy
A B
E
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Figure 6. Human AVD tissue is characterized by early elastic fiber abnormalities. Normal trilaminar aortic valve architecture is seen in early (A)
and late (C) controls. Elastic fiber fragmentation is evident in early-onset AVD (B) and is worse in late-onset AVD (D). There is a significant
decrease in the degree of desmosine content in disease valves when compared to control valves (E). n = 8/group, P < 0.0001;*different from
control.
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Figure 7. Summary model of proposed mechanism of AVD progression. TGFb signaling results in Erk1/2 activation and this in turn stimulates
elastase expression ultimately leading to the downstream effects including ECM abnormalities and inflammation. Refametinib or doxycycline
treatment, inhibiting p-Erk1/2 or elastase activation, significantly reverses progression of disease; however, the fact that neither drug returns
p-Erk to its WT levels suggests that Erk1/2 phosphorylation and elastase expression potentiate reciprocally. AVD, Aortic valve disease.
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using refametinib and doxycycline, which hypothetically
may have an additive or synergistic effect, and in the event
p-Erk1/2 upregulation were completely rescued, evidence
that both Erk and elastases potentiate reciprocally. Interest-
ingly, myofibroblast cell activation and proliferation, which
is markedly increased in Emilin1/ aortic valves, was not
reduced with either treatment, suggesting a VIC myofi-
broblast-like switch occurred prior to treatment, consistent
with the idea that ECM accumulation and disorganization
is an early disease process. It did not alter myofibroblast
activation, angiogenesis or fibrosis. However, the current
study has identified early disease processes involved in pro-
gression that will provide a basis to consider new therapies
for early-onset AVD. In our previous study (Munjal et al.
2014), we showed a significant increase in the average
velocity across the mutant aortic valve, but some aged
valves had pathologic changes without physiologic changes
(i.e., normal velocity) so only a proportion of mutant
valves had increases that would be considered consistent
with clinically significant human AVD. We interpret these
findings to be an age-related phenomenon in part because
we have followed mice to 24 months at which time they are
more likely to have increased velocities. Additional support
of valve pathology is the coexistence of aortic insufficiency
in some mice, a finding that is abnormal and often
observed in the context of a malformed or diseased valve.
Taken together, the data demonstrate a beneficial patholog-
ical response to MEK/Erk inhibition and elastase inhibi-
tion, but it is unclear at present if this extends to
physiologic rescue in the subset that has disease.
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